Raviprakash K - Search Results

1

DNA Vaccine Delivery and Improved Immunogenicity.

Porter KR, Raviprakash K. Porter KR, et al. Among authors: raviprakash k. Curr Issues Mol Biol. 2017;22:129-138. doi: 10.21775/cimb.022.129. Epub 2016 Nov 10. Curr Issues Mol Biol. 2017. PMID: 27831541 Free article. Review.

2

Enhanced immunogenicity and protective efficacy of a tetravalent dengue DNA vaccine using electroporation and intradermal delivery.

Williams M, Ewing D, Blevins M, Sun P, Sundaram AK, Raviprakash KS, Porter KR, Sanders JW. Williams M, et al. Among authors: raviprakash ks. Vaccine. 2019 Jul 26;37(32):4444-4453. doi: 10.1016/j.vaccine.2019.06.083. Epub 2019 Jul 3. Vaccine. 2019. PMID: 31279565

3

Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys.

Raviprakash K, Ewing D, Simmons M, Porter KR, Jones TR, Hayes CG, Stout R, Murphy GS. Raviprakash K, et al. Virology. 2003 Oct 25;315(2):345-52. doi: 10.1016/s0042-6822(03)00542-7. Virology. 2003. PMID: 14585337 Free article.

4

Needle-free injection of DNA vaccines: a brief overview and methodology.

Raviprakash K, Porter KR. Raviprakash K, et al. Methods Mol Med. 2006;127:83-9. doi: 10.1385/1-59745-168-1:83. Methods Mol Med. 2006. PMID: 16988448 Review.

5

Advances in dengue vaccine development.

Raviprakash K, Defang G, Burgess T, Porter K. Raviprakash K, et al. Hum Vaccin. 2009 Aug;5(8):520-8. doi: 10.4161/hv.5.8.9008. Epub 2009 Aug 13. Hum Vaccin. 2009. PMID: 19535912 Review.

6

Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial.

Beckett CG, Tjaden J, Burgess T, Danko JR, Tamminga C, Simmons M, Wu SJ, Sun P, Kochel T, Raviprakash K, Hayes CG, Porter KR. Beckett CG, et al. Among authors: raviprakash k. Vaccine. 2011 Jan 29;29(5):960-8. doi: 10.1016/j.vaccine.2010.11.050. Epub 2010 Nov 25. Vaccine. 2011. PMID: 21111785 Clinical Trial.

7

Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine.

Porter KR, Ewing D, Chen L, Wu SJ, Hayes CG, Ferrari M, Teneza-Mora N, Raviprakash K. Porter KR, et al. Among authors: raviprakash k. Vaccine. 2012 Jan 5;30(2):336-41. doi: 10.1016/j.vaccine.2011.10.085. Epub 2011 Nov 12. Vaccine. 2012. PMID: 22085548

8

A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits.

Raviprakash K, Luke T, Doukas J, Danko J, Porter K, Burgess T, Kochel T. Raviprakash K, et al. Hum Vaccin Immunother. 2012 Dec 1;8(12):1764-8. doi: 10.4161/hv.21806. Epub 2012 Oct 2. Hum Vaccin Immunother. 2012. PMID: 23032166 Free PMC article.

9

Tetravalent DNA vaccine product as a vaccine candidate against dengue.

Porter KR, Teneza-Mora N, Raviprakash K. Porter KR, et al. Among authors: raviprakash k. Methods Mol Biol. 2014;1143:283-95. doi: 10.1007/978-1-4939-0410-5_17. Methods Mol Biol. 2014. PMID: 24715294

10

Nucleic acid (DNA) immunization as a platform for dengue vaccine development.

Porter KR, Raviprakash K. Porter KR, et al. Among authors: raviprakash k. Vaccine. 2015 Dec 10;33(50):7135-40. doi: 10.1016/j.vaccine.2015.09.102. Epub 2015 Oct 14. Vaccine. 2015. PMID: 26458805 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52 results

Search Page

Filters